

News Release

Suven Inc is presenting at Biotech Showcase™ 2016 and participating in the 34th Annual J.P. Morgan Healthcare Conference during January 11th to 14th, 2016 at San Francisco

HYDERABAD, INDIA (Jan 11, 2016) – Suven Inc a wholly owned subsidiary of Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of the unmet medical needs in neurodegenerative disorders today announced that it is participating in the **34th J.P. Morgan Healthcare Conference being held in San Francisco, USA during 11th to 14th Jan 2016 and presenting at Biotech Showcase 2016 on 11th Jan 2016 at 11.30 am PT.**

J.P. Morgan Healthcare conference is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers who will deliver presentations to more than 4,000 investors. This conference puts you at the center of the investment and partnering community and provides an open format to connect with the funding partners.

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Mr.Venkat Jasti is scheduled to discuss the company's corporate overview, business strategy and clinical development pipeline **at Biotech Showcase 2016** where the world's top notch investment professionals will present along with the most innovative companies who are decision makers.

Mr.Venkat Jasti and other members of the management team will be available for one-on-one meetings at the conference. Members of the investment community who are interested in meeting with management should contact Mr . Sunder, VP Corporate Affairs of Suven at (732) 718-9024 or vsunder@suven.com.

Suven Inc's near-term focus is to develop the product candidate **SUVN-502**, for the treatment of Alzheimer's disease and other forms of dementia with the ongoing phase 2a multicenter, randomized, double-blind, parallel group, 26-week, placebo-controlled study of 50 mg and 100 mg of suvn-502 in subjects with moderate Alzheimer's disease currently treated with Donepezil Hydrochloride and Memantine Hydrochloride.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;